EMA Phases out Follow-Up Measures - - BioPharm International

ADVERTISEMENT

EMA Phases out Follow-Up Measures



The European Medicines Agency and its Committee for Medicinal Products for Human Use (CHMP) have started to classify all post-authorization measures for human medicines as it phases out follow-up measures to marketing authorizations. The new classification system is being phased in a stepwise manner. Post-authorization measures will be classified as either: conditions in Annex II (obligations or specific obligations to fulfill post-authorization measures); additional pharmacovigilance activities in the risk-management plan; or recommendations for further development.

EMA and CHMP are reclassifying all outstanding unclassified follow-up measures, starting in August 2012. The first phase of the new classification system tackled initial marketing-authorization-application opinions as of June 2011, followed by post-authorization procedures starting in November 2011.

According to EMA, “Follow-up measures were measures applied to marketing authorizations, setting out studies and other activities that the Agency and CHMP had asked the marketing-authorization holder to perform.” Affected marketing-authorization holders will receive an outcome fax that includes information about the new classification for each of their applicable products.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Suppliers Seek to Boost Single-Use Technology
August 21, 2014
Bristol-Myers Squibb and Celgene Collaborate on Immunotherapy and Chemotherapy Combination Regimen
August 20, 2014
USP Center in Ghana Receives International Lab Accreditation
August 15, 2014
USP Awards Analytical Research
August 15, 2014
FDA Warns about Fraudulent Ebola Treatments
August 15, 2014
Author Guidelines

Click here